Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7872
Peer-review started: August 5, 2023
First decision: August 30, 2023
Revised: September 12, 2023
Accepted: November 9, 2023
Article in press: November 9, 2023
Published online: November 16, 2023
Processing time: 102 Days and 19.2 Hours
Pediatric-onset systemic lupus erythematosus (SLE) is typically more severe than adult-onset SLE, with a higher incidence of nervous system involvement. Chorea is a relatively rare neurological complication reported in 2.4%-7% of SLE patients. In particular, chorea induced by glucocorticoid dose reduction is even rarer. Herein, we report the case of a girl with SLE, who developed chorea during the process of glucocorticoid therapy reduction.
We describe a 14-year-old girl who was diagnosed with SLE. She was treated with methylprednisolone and rituximab, and her symptoms improved. On the second day after the methylprednisolone dose was reduced according to the treatment guidelines, the patient developed chorea. Her condition improved after adjusting her glucocorticoid regimen.
This case is a reminder that extra attention to chorea is required in SLE patients during glucocorticoid dose reduction.
Core Tip: Chorea can be induced by glucocorticoid dose reduction in patients with pediatric-onset systemic lupus erythematosus (SLE). Patients with SLE should be closely monitored during glucocorticoid reduction.